Cannabis-Like drugs may unlock diabetes secrets
NCT ID NCT01517100
First seen Jun 24, 2026 · Last updated Aug 07, 2026 · Updated 6 times
Summary
This study tested two drugs that act on the body's endocannabinoid system—nabilone and CP-945,598—to see how they affect insulin production and sensitivity. Forty-five healthy men aged 21 to 55 took part in four visits, each receiving a different drug combination. The goal was to better understand how this system regulates insulin, which could lead to new diabetes treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Nabilone and CP-945,598
- What this could lead to
- If successful, this could point toward new treatment approaches for type 2 diabetes by targeting the endocannabinoid system.
- What could go wrong
- This is a small, early-phase study in healthy men, not people with diabetes. Results may not translate to real-world treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institute of Aging, Clinical Research Unit
Baltimore, Maryland, 21224, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults